Ironwood醫藥 IRWD 深 滬
等待開盤 06-25 09:30:00 美东时间
3.91
+0.050
+1.30%
華盛通- 最 高4.005
- 今 開3.802
- 成交量 176.45万股
- 最 低 3.802
- 昨 收 3.86
- 總市值 6.44亿
- 52周最高 5.78
- 市盈率 靜 26.53
- 換手率 1.07%
- 52周最低 0.6701
- 委 比 -60.57%
- 總股本 1.65亿
- 歷史最高 18.915
- 量 比 0.71
- 振 幅 5.26%
- 歷史最低 0.5271
- 每 手 1
- 風險率 1.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ironwood Pharma Strengthens Balance Sheet With Note Repayment
Ironwood Pharma ( ($IRWD) ) just unveiled an announcement. On June 15, 2026, Ir...
06-16 05:07
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026
Ironwood Pharmaceuticals (($IRWD)) has held its Q1 earnings call. Read on for t...
06-02 08:30
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation
Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children...
05-27 23:00
FDA approves Ironwood’s Linzess for functional constipation in children aged 2 and older
FDA approves Ironwood’s Linzess for functional constipation in children aged 2 and older FDA cleared expanded use of Ironwood’s Linzess for functional constipation in children aged 2-5 years. Label expansion is backed by a 12-week Phase 3 trial; Linzess 72 mcg improved spontaneous bowel movements ve
05-27 22:02
Small-cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
05-26 22:20
Kyverna Therapeutics appoints Greg Martini as CFO
Kyverna Therapeutics (KYTX) said on Monday it appointed Greg Martini as chief financial officer as the company prepares for a potential commercial launch of its autoimmune disease cell therapy candida...
05-18 20:16
Top 10 small‑cap value picks: lowest forward P/Es and strong profitability
In a market where valuations have been stretched and volatility has made stock-picking increasingly difficult, forward price-to-earnings ratios offer a straightforward lens for identifying potentially...
05-18 18:43
Ironwood Pharma drops after CFO transition
Ironwood Pharmaceuticals (IRWD) lost ~12% on Wednesday after the bowel disease drugmaker announced the appointment of an interim chief financial officer following the resignation of its current CFO, G...
05-13 23:22
Ironwood Pharmaceuticals Affirms FY2026 Sales Guidance of $450.000M-$475.000M vs $458.593M Est
Ironwood Pharmaceuticals (NASDAQ:IRWD) affirms FY2026 sales outlook from $450.000 million-$475.000 million to $450.000 million-$475.000 million vs $458.593 million estimate.
05-07 19:08
